PITTSBURGH, May 16, 2022
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global
pharmaceutical company, today published its 2021 Sustainability
Report, outlining the company's 2021 achievements and progress
across key areas including Access and Global Health, Employees,
Environmental Stewardship and Community Engagement and
including details on Viatris' continued efforts to support
employees and their families while maintaining a stable supply of
medicines during the ongoing COVID-19 pandemic.
As part of the report, the company committed to initial
company-wide and multi-year goals in three key areas – access, the
environment and diversity, equity and inclusion (DE&I).
These include providing antiretroviral (ARV) therapy equivalent to
a total of 30 million patients, including more than two million
children living with HIV/ AIDS, between 2022 and the end of 2025;
impacting 100 million patients via healthcare professional
education and outreach regarding prevention, diagnosis and
treatment options for cardiovascular disease, diabetes, cancer and
other important chronic conditions to improve outcomes through the
NCD Academy by the end of 2025. Viatris has committed to reducing
absolute Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030
and reducing Scope 3 GHG emissions covering purchase goods and
services, capital goods, fuel and energy related alternatives and
upstream transportation and distribution 25% by 2030. The company
has also set goals to enhance DE&I in support of attracting,
developing and retaining diverse talent and building a more
inclusive environment.
"At Viatris, we believe companies can be a force for good. Our
colleagues around the world strive to make a positive difference
and during our first full year as Viatris, they truly exemplified
the power that lies in collaboration, focus and resilience," said
Michael Goettler, CEO for Viatris.
"We are proud of the strong foundation we have built, the progress
we have made and our commitment to acting responsibly as we support
providing sustainable access to medicine for patients around the
world, regardless of geography or circumstance, while building a
simpler, stronger and more focused company."
Here are some of Viatris' key initiatives, progress and
accomplishments in 2021, in collaboration with our partners:
- Approximately 40% of adults and more than 60% of children being
treated for HIV used a Viatris product
- More than 80 billion doses of medicine sold across more than
165 countries and territories, reaching approximately 90% of low-
and lower-middle-income countries with approximately 7.7 billion
doses
- Established a formal program for building DE&I, beginning
with understanding the current makeup of our workforce to inform
how we will embed DE&I throughout the organization, support
representation and enhance the employee experience overall
- Signed on to the UN Global Compact CEO Water Mandate and UN
Women's Empowerment Principles
- Approximately 500 million doses of medicines donated across a
variety of therapeutic areas by working through a trusted network
of partners
"At Viatris, our commitment to access to medicine and supporting
resilient healthcare systems by advancing sustainable and
responsible operations truly is a collective mission, realized
through the dedication of colleagues across the organization," said
Lara Ramsburg, Head of Corporate
Affairs of Viatris.
Viatris is dedicated to transparent annual reporting on
environmental, social and governance matters, continuously working
to further enhance its disclosures.
To learn more about how the company partners
with stakeholders throughout the globe to address some of
the world's most pressing health, environmental and social
issues, click here.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company,
empowering people worldwide to live healthier at every stage of
life. We provide access to medicines, advance sustainable
operations, develop innovative solutions and leverage our
collective expertise to connect more people to more products and
services through our one-of-a-kind Global Healthcare Gateway®.
Formed in November 2020, Viatris brings together scientific,
manufacturing and distribution expertise with proven regulatory,
medical, and commercial capabilities to deliver high-quality
medicines to patients in more than 165 countries and territories.
Viatris' portfolio comprises more than 1,400 approved molecules
across a wide range of therapeutic areas, spanning both
non-communicable and infectious diseases, including globally
recognized brands, complex generic and branded medicines, a
portfolio of biosimilars and a variety of over-the-counter consumer
products. With approximately 37,000 colleagues globally, Viatris is
headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com
and investor.viatris.com, and connect with us on Twitter at
@ViatrisInc, LinkedIn and YouTube.
Forward-Looking Statements
This press release includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements about the company
committing to initial company-wide and multi-year goals in three
key areas – access, the environment and DE&I; that these
include providing antiretroviral (ARV) therapy equivalent to a
total of 30 million patients, including more than two million
children living with HIV/ AIDS, between 2022 and the end of 2025;
impact 100 million patients via healthcare professional education
and outreach regarding prevention, diagnosis and treatment options
for cardiovascular disease, diabetes, cancer and other important
chronic conditions to improve outcomes through the NCD Academy by
the end of 2025; that Viatris has committed to reducing absolute
Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 and
reducing Scope 3 GHG emissions covering purchase goods and
services, capital goods, fuel and energy related alternatives and
upstream transportation and distribution 25% by 2031; and that the
company has also set goals to enhance DE&I in support of
attracting, developing and retaining diverse talent and building a
more inclusive environment. Because forward-looking statements
inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such
statements. Factors that could cause or contribute to such
differences include, but are not limited to: the potential impact
of public health outbreaks, epidemics and pandemics, including the
ongoing challenges and uncertainties posed by the COVID-19
pandemic; the pending transaction between Viatris and Biocon
Biologics Limited, pursuant to which Viatris will contribute its
biosimilar products and programs to Biocon Biologics in exchange
for cash consideration and a convertible preferred equity interest
in Biocon Biologics, may not achieve its intended benefits; the
integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the
"Upjohn Business"), which combined to form Viatris (the
"Combination") and the implementation of our global restructuring
initiatives being more difficult, time consuming or costly than
expected, or being unsuccessful; the ability to achieve expected
benefits, synergies, and operating efficiencies in connection with
the Combination or its restructuring initiatives within the
expected timeframe or at all; actions and decisions of healthcare
and pharmaceutical regulators; changes in healthcare and
pharmaceutical laws and regulations in the U.S. and abroad; any
regulatory, legal or other impediments to Viatris' ability to bring
new products to market, including but not limited to "at-risk"
launches; Viatris' or its partners' ability to develop,
manufacture, and commercialize products; the scope, timing and
outcome of any ongoing legal proceedings, and the impact of any
such proceedings; any significant breach of data security or data
privacy or disruptions to our information technology systems; risks
associated with international operations; the ability to protect
intellectual property and preserve intellectual property rights;
changes in third-party relationships; the effect of any changes in
Viatris' or its partners' customer and supplier relationships and
customer purchasing patterns; the impacts of competition; changes
in the economic and financial conditions of Viatris or its
partners; uncertainties and matters beyond the control of
management; and the other risks described in Viatris' filings with
the Securities and Exchange Commission (SEC). Viatris routinely
uses its website as a means of disclosing material information to
the public in a broad, non-exclusionary manner for purposes of the
SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no
obligation to update these statements for revisions or changes
after the date of this release other than as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-publishes-sustainability-report-highlighting-2021-progress-achievements-and-goals-301547592.html
SOURCE Viatris Inc.